J&J Questions $158M Settlement Of Texas' Risperdal Suit
The Johnson & Johnson unit, Janssen Pharmaceuticals Inc., declined to comment on what would be discussed in court, saying the details are private and not for public disclosure.
"We are not disputing the settlement agreement that was reached in Texas. Janssen remains committed to paying the agreed...
To view the full article, register now.